Background: Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are an important new class of HIV-1 inhibitors. ALLINIs bind at the IN catalytic core domain (CCD) dimer interface in the LEDGF/p75 binding pocket. Consequently, they inhibit HIV-1 IN interaction with its cellular cofactor LEDGF/p75 as well as promote aberrant IN multimerization. Selection of viral strains emerging under ALLINI pressure has revealed mutations at the IN dimer interface near the inhibitor binding site. Here we have investigated A124D and H171T IN substitutions that confer resistance to potent ALLINI BI-D. Methodology: We used biochemical, x-ray crystallography and virology methods to understand the mechanisms for IN H171T and A124D resistance to ALLINI BI-D. Specifically, we utilized size exclusion chromatography (SEC) and dynamic light scattering (DLS) to monitor BI-D induced aberrant multimerization of IN. Homogeneous-time resolved fluorescence (HTRF)-based assays were used to determine the potency of BI-D for inhibiting IN-LEDGF/p75 interactions. Furthermore, we have solved the x-ray crystal structure of BI-D bound to HIV-1 IN CCD containing the H171T substitution. Additionally, binding free energy calculations were performed on complexes of BI-D and IN(WT and H171T). Results: Viruses containing the A124D or H171T mutations in IN are significantly resistant to BI-D treatment in infected cells. SEC and DLS analysis of BI-D interactions with purified mutant INs revealed differing mechanisms of resistance with respect to aberrant multimerization. BI-D treatment promoted higher order oligomerization of WT and H171T IN, whereas the compound did not significantly affect A124D IN. However, H171T IN exhibited significantly reduced binding affinity with LEDGF/p75, whereas WT and the A124D IN bound LEDGF/p75 with similar affinities. Furthermore, x-ray crystallography and binding free energy calculations have revealed the importance of the doubly protonated form and the Nd-protonated tautomer states of H171 for binding BI-D and LEDGF/p75. Conclusions: ALLINI BI-D resistance IN mutations H171T and A124D underscore the inhibitors bimodal mechanism of action. A124D IN overcomes BI-D inhibition by avoiding BI-D induced aberrant multimerization, while the H171T substitution adversely affects BI-D binding to HIV-1 IN and concomitantly affects IN-LEDGF/p75 binding.